Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1
NCT06373263 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128
Last updated 2025-12-08
Summary
Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. The investigators plan to conduct a series of randomized controlled trials among people with scleroderma, a rare autoimmune disease, in a large international cohort, to identify the most effective methods for communicating study results with patients.
The first trial in the series will compare a research dissemination tool (infographic) against a plain-language summary comparator. Participants will be randomly assigned to receive the dissemination tool or comparator. Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. Our results can be used by researchers and patient organizations who disseminate research results so that they can tailor the way they disseminate results to patient needs.
Conditions
- Scleroderma
- Systemic Sclerosis
Interventions
- OTHER
-
Plain-language summary
Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
- OTHER
-
Dissemination Tool (Infographic)
The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
Sponsors & Collaborators
-
Lady Davis Institute
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-05
- Primary Completion
- 2025-12-19
- Completion
- 2026-01-02
More Related Trials
-
Making it Work Program for Systemic Sclerosis
NCT06338722 ·Status: COMPLETED ·Phase: NA
-
SPIN Self-Management Feasibility Trial
NCT03914781 ·Status: COMPLETED ·Phase: NA
-
A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis
NCT03766243 ·Status: COMPLETED ·Phase: NA
-
Taking Charge of Systemic Sclerosis
NCT02494401 ·Status: COMPLETED ·Phase: NA
-
Delving Into Participation Trends of Scleroderma Clinical Trials
NCT06264492 ·Status: NOT_YET_RECRUITING
-
Self-management Telehealth Program for Scleroderma
NCT06990386 ·Status: COMPLETED ·Phase: NA
-
6-minute Pegboard Ring Test in Patients with Scleroderma
NCT06588959 ·Status: NOT_YET_RECRUITING
-
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
NCT05726630 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
NCT02349009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
NCT02396238 ·Status: COMPLETED ·Phase: NA
-
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
NCT03629002 ·Status: UNKNOWN
-
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
NCT02165111 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis
NCT01813279 ·Status: COMPLETED ·Phase: NA
-
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
NCT01743612 ·Status: COMPLETED ·Phase: NA
-
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
NCT05171114 ·Status: COMPLETED ·Phase: NA
-
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
NCT01881529 ·Status: COMPLETED
-
Pragmatic Clinical Trials in Scleroderma
NCT03610217 ·Status: UNKNOWN ·Phase: NA
-
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226 ·Status: RECRUITING ·Phase: NA
-
Exercise in People With Systemic Sclerosis
NCT05234671 ·Status: COMPLETED ·Phase: NA
-
RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue
NCT04908943 ·Status: COMPLETED ·Phase: NA
-
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis
NCT03268330 ·Status: UNKNOWN
-
Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis
NCT01834157 ·Status: UNKNOWN
-
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
NCT06502678 ·Status: NOT_YET_RECRUITING
-
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
NCT00278525 ·Status: COMPLETED ·Phase: PHASE2
-
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
NCT03198689 ·Status: COMPLETED ·Phase: PHASE2